Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29757436 | 0.86 | GABRA1 (0.33) | GABRA1GABRB2TSHRGABRG2GABRB3 | |
| SCHEMBL23363406 | 0.86 | GABRA1 (0.33) | GABRA1GABRB2TSHRGABRG2GABRB3 | |
| SCHEMBL20818183 | 0.86 | GABRA1 (0.33) | GABRA1GABRB2TSHRGABRG2GABRB3 | |
| SCHEMBL20818418 | 0.83 | BTK (0.32) | GABRA1GABRB2CYP3A4HIF1ASLC6A2 | |
| SCHEMBL19880468 | 0.80 | GABRA1 (0.39) | GABRA1GABRB2TSHRGABRG2GABRB3 | |
| SCHEMBL2082260 | 0.80 | GABRA1 (0.39) | GABRA1GABRB2TSHRGABRG2GABRB3 | |
| SCHEMBL25688689 | 0.79 | NFE2L2 (0.33) | — | |
| SCHEMBL20831318 | 0.78 | LMNA (0.37) | TSHRLMNAHIF1ATDP1HTT | |
| SCHEMBL19124254 | 0.77 | GABRA1 (0.36) | GABRA1GABRB2TSHRGABRG2GABRB3 | |
| SCHEMBL19685354 | 0.76 | PDXK (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-20210171500-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2020-09-15 | — | — | US | disclosed |
| US-20190292178-A9 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10023588-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-17 | — | — | US | disclosed |
| US-9879003-B2 | Host targeted inhibitors of dengue virus and other viruses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-21 | — | — | US | disclosed |
| EP-2714648-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20150166532-A1 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-18 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | GABRA1 4608/4885GABRB2 4079/4885TSHR 4752/4885 |
| US-20150166532-A1 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | RPL17, RPL26, RPL35 | GABRA1 4074/4885GABRB2 4539/4885TSHR 4294/4885 |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, RASGRP1 | GABRA1 4056/4885GABRB2 4215/4885TSHR 2481/4885 |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | GABRA1 1083/4885GABRB2 1515/4885TSHR 196/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | GABRA1 4608/4885GABRB2 4079/4885TSHR 4752/4885 |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | GABRA1 3720/4885GABRB2 3528/4885TSHR 4378/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | GABRA1 3698/4885GABRB2 3315/4885TSHR 3159/4885 |
| US-20190292178-A9 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | RPL26, RPL35, RPL5 | GABRA1 4000/4885GABRB2 4506/4885TSHR 4645/4885 |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | GABRA1 462/4885GABRB2 452/4885TSHR 2837/4885 |
| US-10023588-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | GABRA1 4608/4885GABRB2 4079/4885TSHR 4752/4885 |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | GABRA1 2372/4885GABRB2 1479/4885TSHR 1739/4885 |
| US-20210171500-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | GABRA1 1083/4885GABRB2 1515/4885TSHR 196/4885 |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | GABRA1 1083/4885GABRB2 1515/4885TSHR 196/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | GABRA1 4398/4885GABRB2 3419/4885TSHR 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.